Contact
searchSearch
HMP Global
Login

Colorectal Cancer

Colorectal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Paul Oberstein, MD
Videos
Amivantamab in Chemorefractory Metastatic Colorectal Cancer
05/27/2026
Paul Oberstein, MD
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
Paul Oberstein, MD, discusses...
05/27/2026
Oncology
Ismail Gögenur, MD, DMSc
Videos
Neoadjuvant Pembrolizumab in Localized Mismatch Repair–Deficient Colon Cancer
05/15/2026
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc,...
05/15/2026
Oncology
Andrew Renehan, MD, PhD
Videos
Survival and Quality of Life Drive Treatment Preferences in Rectal Cancer
04/16/2026
Andrew Renehan, MD, PhD
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD,...
04/16/2026
Oncology
Davide Ciardiello, MD
Videos
HER2 Alterations Predict Inferior Survival With Anti-EGFR Therapy in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
03/11/2026
Davide Ciardiello, MD
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses...
03/11/2026
Oncology
Veronica Conca, MD
Videos
mFOLFOXIRI Plus Panitumumab Improves Overall Survival in RAS/BRAF Wild-Type mCRC
03/10/2026
Veronica Conca, MD
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses...
03/10/2026
Oncology
Campbell Roxburgh, MD
Videos
Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer
02/10/2026
Campbell Roxburgh, MD
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses...
02/10/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
01/16/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses...
01/16/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and mFOLFOX6 for Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer
09/10/2025
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses...
09/10/2025
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use